Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Genedrive ( (GB:GDR) ).
Genedrive plc announced the superior clinical performance of its Genedrive® CYP2C19-ID Kit, published in the Journal of Molecular Biology. The kit, recommended by NICE for use in the NHS, excels in speed, accuracy, and cost-effectiveness compared to laboratory testing, identifying critical genetic variants undetected by alternative platforms. This advancement positions Genedrive to capitalize on the growing clinical pharmacogenetics market, enhancing patient outcomes and access to healthcare while reducing financial burdens.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company specializing in point of care diagnostics. It develops and commercializes cost-effective, rapid, and simple-to-use platforms for diagnosing genetic variants, aiding clinicians in making informed decisions on medication and dosage for effective treatments, particularly in emergency healthcare settings. The company is at the forefront of point of care pharmacogenetic testing, with flagship products like the Genedrive® MT-RNR1 ID Kit and CYP2C19 ID Kit, both recommended by NICE for use in the UK NHS.
YTD Price Performance: -65.00%
Average Trading Volume: 9,204,928
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £12.36M
For detailed information about GDR stock, go to TipRanks’ Stock Analysis page.
